IL105986A - Pharmaceutical preparations containing triazine compounds for the prevention or reduction of tolerable dependence or the opposite of dependency - Google Patents

Pharmaceutical preparations containing triazine compounds for the prevention or reduction of tolerable dependence or the opposite of dependency

Info

Publication number
IL105986A
IL105986A IL10598693A IL10598693A IL105986A IL 105986 A IL105986 A IL 105986A IL 10598693 A IL10598693 A IL 10598693A IL 10598693 A IL10598693 A IL 10598693A IL 105986 A IL105986 A IL 105986A
Authority
IL
Israel
Prior art keywords
dependence
inducing agent
tolerance
compound
preventing
Prior art date
Application number
IL10598693A
Other languages
English (en)
Hebrew (he)
Other versions
IL105986A0 (en
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929212495A external-priority patent/GB9212495D0/en
Priority claimed from GB939308654A external-priority patent/GB9308654D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of IL105986A0 publication Critical patent/IL105986A0/xx
Publication of IL105986A publication Critical patent/IL105986A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL10598693A 1992-06-12 1993-06-11 Pharmaceutical preparations containing triazine compounds for the prevention or reduction of tolerable dependence or the opposite of dependency IL105986A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929212495A GB9212495D0 (de) 1992-06-12 1992-06-12
GB939308654A GB9308654D0 (en) 1993-04-27 1993-04-27 Therapeutic triazine compounds and use

Publications (2)

Publication Number Publication Date
IL105986A0 IL105986A0 (en) 1993-10-20
IL105986A true IL105986A (en) 1998-12-06

Family

ID=26301060

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10598693A IL105986A (en) 1992-06-12 1993-06-11 Pharmaceutical preparations containing triazine compounds for the prevention or reduction of tolerable dependence or the opposite of dependency

Country Status (23)

Country Link
US (1) US5801171A (de)
EP (1) EP0644763B1 (de)
JP (1) JP3439211B2 (de)
KR (1) KR100268823B1 (de)
AT (1) ATE147980T1 (de)
AU (1) AU688729B2 (de)
CA (1) CA2137782A1 (de)
CZ (1) CZ284061B6 (de)
DE (1) DE69307705T2 (de)
DK (1) DK0644763T3 (de)
ES (1) ES2097516T3 (de)
GB (1) GB2282326A (de)
GR (1) GR3022671T3 (de)
HR (1) HRP930964B1 (de)
IL (1) IL105986A (de)
MY (1) MY109330A (de)
NO (1) NO306451B1 (de)
NZ (1) NZ253260A (de)
SI (1) SI9300318A (de)
SK (1) SK279730B6 (de)
TW (1) TW284689B (de)
WO (1) WO1993025207A1 (de)
YU (1) YU48573B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0059987B1 (de) * 1979-06-01 1985-08-14 The Wellcome Foundation Limited Alpha-Cyano-alpha-((N-guanidino)-imino)toluene
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds

Also Published As

Publication number Publication date
GB2282326A (en) 1995-04-05
DE69307705D1 (de) 1997-03-06
DE69307705T2 (de) 1997-05-22
YU41093A (sh) 1996-10-09
DK0644763T3 (da) 1997-07-28
MY109330A (en) 1997-01-31
GB9423697D0 (en) 1995-01-11
TW284689B (de) 1996-09-01
HRP930964A2 (en) 1996-02-29
JP3439211B2 (ja) 2003-08-25
AU688729B2 (en) 1998-03-19
KR950701814A (ko) 1995-05-17
EP0644763B1 (de) 1997-01-22
SK279730B6 (sk) 1999-02-11
AU4345293A (en) 1994-01-04
GR3022671T3 (en) 1997-05-31
HRP930964B1 (en) 2000-06-30
NZ253260A (en) 1997-05-26
CZ284061B6 (cs) 1998-08-12
SI9300318A (en) 1994-03-31
YU48573B (sh) 1998-12-23
ATE147980T1 (de) 1997-02-15
WO1993025207A1 (en) 1993-12-23
EP0644763A1 (de) 1995-03-29
CA2137782A1 (en) 1993-12-23
IL105986A0 (en) 1993-10-20
NO944790D0 (no) 1994-12-09
NO306451B1 (no) 1999-11-08
US5801171A (en) 1998-09-01
JPH07507790A (ja) 1995-08-31
KR100268823B1 (ko) 2000-12-01
CZ312894A3 (en) 1995-07-12
ES2097516T3 (es) 1997-04-01
SK153494A3 (en) 1996-01-10
NO944790L (no) 1994-12-09

Similar Documents

Publication Publication Date Title
KR100196674B1 (ko) 디페닐부틸-피페라진카르복사미드를 이용한 물질 남용 장애의 치료방법 및 그를 함유하는 약제학적 조성물
HU202108B (en) Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
Bergman et al. The reinforcing properties of diazepam under several conditions in the rhesus monkey
US5629336A (en) Use of glycine/NMDA receptor ligands for the treatment of drug dependence and withdrawal
US5712277A (en) Use of 3,5-diamino-6-(2,3-dichlororophenyl) -1,2,4-triazine for the treatment of pain and oedema
WO1992014464A1 (en) Use of sigma receptor antagonists for treatment of cocaine abuse
US4181726A (en) Method of alleviating pruritis
EP0644763B1 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4,-triazinisethionat zur behandlung und vorbeugung von drogenabhaengigkeit,-toleranz und- sensibilisierung
WO2000025766A2 (en) Use of nk antagonist for treating gastric asthma
US4563460A (en) Quinoline and quinazoline derivatives for treating gastrointestinal motility dysfunctions
US4617311A (en) Antiasthmatic method
US4829068A (en) Treatment of disorders of the gastro-intestinal tract
US4562188A (en) Triazinones for treating irritable bowel syndrome
JPH0232020A (ja) モルフィン鎮痛治療における耐性発現の抑制方法および薬剤
JP3713271B6 (ja) 3,5−ジアミノ−6−(2,3−ジクロロフェニル)−1,2,4−トリアジンの浮腫および痛みの治療のための使用
Bewley et al. Opioid analgesics and narcotic antagonists
Spector Management of chronic idiopathic urticaria
JPS6159289B2 (de)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
RH1 Patent not in force